Diagnosis and prognosis of multiple sclerosis

Patent metadata

Field	Value
Publication number	US-10487360-B2
Application number	US-201615093456-A
Country	US
Kind code	B2
Filing date	Apr 7, 2016
Priority date	Aug 24, 2010
Publication date	Nov 26, 2019
Grant date	Nov 26, 2019

Abstract

The present invention provides a method for determining whether an individual with relapsing-remitting multiple sclerosis will suffer a relapse or respond to treatment for MS. A ratio of mRNA levels of Response Gene to Complement-32, FasL or IL-21 to L13 determined for an individual provides a normalized level which is compared to a cut-off value. A normalized level of Response Gene to Complement-32 greater than 2.52, a normalized level of FasL greater than 85.4 and a normalized level of IL-21 less than 11.9, respectively, indicates the individual will have or is having a relapse of multiple sclerosis. Also provided are methods for determining whether an individual will respond positively or is responding positively to glatiramer treatment and whether the individual is in a period of stable disease or is not at risk for relapse of multiple sclerosis by comparing normalized levels with the respective cut-off levels.

First claim

What is claimed is:

1. A method for treating an individual with relapsing-remitting multiple sclerosis that is at risk for a relapse comprising the steps of:
a) collecting a peripheral blood sample from the individual;
b) isolating peripheral blood mononuclear cells from said peripheral blood sample;
c) measuring Response Gene to Complement-32 mRNA in said peripheral blood mononuclear cells;
d) measuring L13 mRNA in said peripheral blood mononuclear cells;
e) diagnosing the individual as being at risk for a relapse based on a ratio of measured Response Gene to Complement-32 mRNA to the L13 mRNA of 1.27 or less; and
f) administering a multiple sclerosis treating drug to the individual diagnosed as being at risk of relapse.

2. The method of claim 1 , further comprising repeating the steps a) to d) on the individual daily, weekly or monthly.

3. The method of claim 1 , further comprising:
measuring at least one of FasL mRNA or IL-21 mRNA in the peripheral blood mononuclear cells;
diagnosing the individual as being at risk for relapse based on a ratio of at least one of the measured FasL mRNA to L13 mRNA of 52.6 or less or the measured IL-21 mRNA to L13 mRNA of 16.9 or greater.

4. The method of claim 1 , wherein the multiple sclerosis treating drug is glatiramer acetate or interferon-β.

5. A method for treating an individual with relapsing-remitting multiple sclerosis that is at risk for a relapse comprising the steps of:
a) collecting a peripheral blood sample from the individual;
b) isolating peripheral blood mononuclear cells from said peripheral blood sample;
c) measuring FasL mRNA in said peripheral blood mononuclear cells;
d) measuring L13 mRNA in said peripheral blood mononuclear cells;
e) diagnosing the individual as being at risk for a relapse based on a ratio of measured FasL mRNA to L13 mRNA of 52.6 or less; and
f) administering a multiple sclerosis treating drug to the individual diagnosed as being at risk of relapse.

6. The method of claim 5 , further comprising repeating the steps a) to d) on the individual daily, weekly or monthly.

7. The method of claim 5 further comprising,
measuring at least one of Response Gene to Complement-32 mRNA or IL-21 mRNA in the peripheral blood mononuclear cells;
diagnosing the individual as being at risk for relapse based on a ratio of at least one of the measured Response Gene to Complement-32 mRNA to L13 mRNA of 1.27 or less or the measured IL-21 mRNA to L13 mRNA.

8. The method of claim 5 , wherein said multiple sclerosis treating drug is glatiramer acetate or interferon-β.

9. A method for treating an individual with relapsing-remitting multiple sclerosis that is at risk for a relapse comprising the steps of:
a) collecting a peripheral blood sample from the individual;
b) isolating peripheral blood mononuclear cells from said peripheral blood sample;
c) measuring IL-21 mRNA in said peripheral blood mononuclear cells;
d) measuring L13 mRNA in said peripheral blood mononuclear cells;
e) diagnosing the individual as being at risk for a relapse based on a ratio of IL-21 mRNA to L13 mRNA of 16.9 or greater; and
f) administering a multiple sclerosis treating drug to the individual diagnosed as being at risk of relapse.

10. The method of claim 9 , further comprising repeating the steps a) to d) on the individual daily, weekly or monthly.

11. The method of claim 9 , further comprising:
measuring at least one of Response Gene to Complement-32 mRNA or FasL in the peripheral blood mononuclear cells;
diagnosing the individual as being at risk for relapse based on a ratio of at least one of the measured Response Gene to Complement-32 mRNA to L13 mRNA of 1.27 or less or the measured FasL mRNA to L13 mRNA of 52.6 or less.

12. The method of claim 9 , wherein said multiple sclerosis treating drug is glatiramer acetate or interferon-β.

13. A method for treating an individual with relapsing-remitting multiple sclerosis that is at risk for a relapse, comprising, the steps of:
a) collecting a peripheral blood sample from the individual;
b) isolating peripheral blood mononuclear cells from said peripheral blood sample;
c) measuring Response Gene to Complement-32 mRNA, FasL mRNA, IL-21 mRNA, and L13 mRNA in said peripheral blood mononuclear cells;
d) diagnosing the individual as being at risk for a relapse based on a ratio of measured Response Gene to Complement-32 mRNA to L13 mRNA of 1.27 or less, measured FasL mRNA to L13 mRNA of 52.6 or less and measured IL-21 mRNA to L13 mRNA of 16.9 or greater;
e) administering a multiple sclerosis treating drug to the individual diagnosed as being at risk of relapse.

14. The method of claim 13 , further comprising repeating the steps a) to c) on the individual daily, wherein when at least one of the ratio of the measured Response Gene to Complement-32 mRNA to L13 mRNA is 2.52 or greater, the ratio of the measured FasL mRNA to L13 mRNA is 85.4 or greater or the ratio of the measured IL-21 mRNA to L13 mRNA is 11.9 or less from one day to the next, the individual will respond or is responding positively to said treatment.

15. The method of claim 13 , further comprising repeating the steps a) to c) on the individual weekly, wherein when at least one of the ratio of the measured Response Gene to Complement-32 mRNA to L13 mRNA is 2.52 or greater, the ratio of the measured FasL mRNA to L13 mRNA is 85.4 or greater or the ratio of the measured IL-21 mRNA to L13 mRNA is 11.9 or less from one week to the next, the individual will respond or is responding positively to said treatment.

16. The method of claim 13 , further comprising repeating the steps a) to c) on the individual monthly, wherein when at least one of the ratio of the measured Response Gene to Complement-32 mRNA to L13 mRNA is 2.52 or greater, the ratio of the measured FasL mRNA to L13 mRNA is 85.4 or greater or the ratio of the measured IL-21 mRNA to L13 mRNA is 11.9 or less from one month to the next, the individual will respond or is responding positively to said treatment.

17. The method of claim 13 , wherein said multiple sclerosis treating drug is glatiramer acetate or interferon-β.

Assignees

• Rus Horea
• Cudrici Cornelia
• Tegla Cosmin
• Univ Maryland
• The Dept Of Veterans Affairs

Inventors

• Rus Horea
• Cudrici Cornelia
• Tegla Cosmin

Classifications

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q1/6883 Primary

  for diseases caused by alterations of genetic material · CPC title

• C12Q2600/112

  Disease subtyping, staging or classification · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title

• C12Q2600/158

  Expression markers · CPC title